Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Recurrent pneumonia due to bronchial carcinoid tumour in a young patient: the role of (111)in-pentetreotide in imaging studies.

García-Talavera P, López-Pedreira MR, Udaondo M, Matilla JM, Villanueva JG, Borrego H.

Arch Bronconeumol. 2015 Mar;51(3):e16-8. doi: 10.1016/j.arbres.2014.01.002. Epub 2014 Feb 24. English, Spanish.

2.

Differentiation between carcinoid and sarcoid with F-18 FDG PET and In-111 pentetreotide.

Avram AM, Mackie GC, Schneider BJ, Kalemkerian GP, Shulkin BL.

Clin Nucl Med. 2006 Apr;31(4):197-200.

PMID:
16550010
3.

Use of radioguided surgery with [111In]-pentetreotide in the management of an ACTH-secreting bronchial carcinoid causing ectopic Cushing's syndrome.

Grossrubatscher E, Vignati F, Dalino P, Possa M, Belloni PA, Vanzulli A, Bramerio M, Marocchi A, Rossetti O, Zurleni F, Loli P.

J Endocrinol Invest. 2005 Jan;28(1):72-8.

PMID:
15816375
4.
5.

Imaging of bronchial carcinoid tumours with indium-111 pentetreotide.

O'Byrne KJ, O'Hare NJ, Freyne PJ, Luke DA, Clancy LJ, Prichard JS, Carney DN.

Thorax. 1994 Mar;49(3):284-6.

6.

Acromegaly as manifestation of a bronchial carcinoid tumour.

Filosso PL, Donati G, Rena O, Oliaro A.

Asian Cardiovasc Thorac Ann. 2003 Jun;11(2):189. No abstract available.

PMID:
12878580
7.

Comment on primary localization of an ectopic ACTH-producing bronchial carcinoid tumor by indium111 pentetreotide scintigraphy.

Reincke M, Allolio B, Arlt W, Körber C.

J Clin Endocrinol Metab. 1999 Sep;84(9):3399-400; author reply 3402-3. No abstract available.

PMID:
10487718
8.

Carcinoid tumours presenting as breast cancer: the utility of radionuclide imaging with 123I-MIBG and 111In-DTPA pentetreotide.

Kaltsas GA, Putignano P, Mukherjee JJ, Satta MA, Lowe DG, Britton KE, Monson JP, Grossman AB, Besser GM.

Clin Endocrinol (Oxf). 1998 Nov;49(5):685-9. Review.

PMID:
10197087
9.

[Cushing's syndrome secondary to bronchial carcinoid tumor: use of octreoScan in the location diagnosis].

Gómez Merino E, Navarro Martínez A, Solís del Pozo JE, Andrés Mompeán E, Requejo R.

An Med Interna. 2003 Jan;20(1):52. Spanish. No abstract available.

PMID:
12666316
10.

Intraoperative detection of a bronchial carcinoid with a radiolabeled somatostatin analog.

Rodriguez JA, Meyers MO, Jacome TH, Failla P, Harrison LH Jr.

Chest. 2002 Mar;121(3):985-8.

PMID:
11888987
11.

Improved visualization of carcinoid liver metastases by indium-111 pentetreotide scintigraphy following treatment with cold somatostatin analogue.

Dörr U, Räth U, Sautter-Bihl ML, Guzman G, Bach D, Adrian HJ, Bihl H.

Eur J Nucl Med. 1993 May;20(5):431-3.

PMID:
8100192
12.

The radioguided 111In-pentetreotide surgery in the management of ACTH-secreting bronchial carcinoid.

Porziella V, Cesario A, Lococo F, Cafarotti S, Margaritora S, D'Errico G, Granone P.

Eur Rev Med Pharmacol Sci. 2011 Jun;15(6):587-91.

PMID:
21796863
13.

[Thoracic SPECT using (111 In-DTPA-D-Phe1)-octreotide in bronchial carcinoid syndrome].

Banzo J, Sebastián A, Prats E, Freile E, García F, Costán J, Razola P, Tomás A, Cegoñino J, Abós MD.

Rev Esp Med Nucl. 1998;17(1):45-8. Spanish.

14.

Focal myocardial uptake in a patient with carcinoid tumor by indium-111-pentetreotide on SPECT/CT.

Mahmood S, Martínez de Llano SR, Grewal RK.

Rev Esp Med Nucl. 2008 Sep-Oct;27(5):355-7.

15.

Somatostatin-receptor scintigraphy of subcutaneous and thyroid metastases from bronchial carcinoid.

Krausz Y, Pfeffer MR, Glaser B, Lafair J.

J Nucl Med. 1996 Sep;37(9):1537-9.

16.

Combined diagnostic imaging with 131I-metaiodobenzylguanidine and 111In-pentetreotide in carcinoid tumours.

Taal BG, Hoefnagel CA, Valdés Olmos RA, Boot H.

Eur J Cancer. 1996 Oct;32A(11):1924-32.

PMID:
8943676
17.

Bronchial carcinoid tumours: a study on clinicopathological features and role of octreotide scintigraphy.

Musi M, Carbone RG, Bertocchi C, Cantalupi DP, Michetti G, Pugliese C, Virotta G.

Lung Cancer. 1998 Nov;22(2):97-102.

PMID:
10022217
18.

Successful localization of an occult ACTH-secreting bronchial carcinoid tumour with 111indium-DTPA labelled octreotide.

Tsagarakis S, Giannakenas C, Vassilakos PJ, Platis O, Belenis I, Kaskarelis J, Rontoyianni D, Thalassinos N.

Clin Endocrinol (Oxf). 1995 Dec;43(6):763-7.

PMID:
8736282
19.

Cushing's syndrome associated with a chemodectoma and a carcinoid tumour.

Tremble JM, Buxton-Thomas M, Hopkins D, Kane P, Bailey D, Harris PE.

Clin Endocrinol (Oxf). 2000 Jun;52(6):789-93. Review.

PMID:
10848885
20.

The octreotide suppression test and [111In-DTPA-D-Phe1]-octreotide scintigraphy in neuroendocrine tumours correlate with responsiveness to somatostatin analogue treatment.

Shi W, Buchanan KD, Johnston CF, Larkin C, Ong YL, Ferguson R, Laird J.

Clin Endocrinol (Oxf). 1998 Mar;48(3):303-9.

PMID:
9578820

Supplemental Content

Support Center